ImClone

Source: blogs.wsj.com --- 1 day ago
The biotech company founded in the '80s is worth more than the leading U.S. automaker, as measured by total stock value. ...

Source: www.investors.com --- 12 hours ago
It turns out Carl Icahn wasn't bluffing after all. He really did have an offer of $70 a share for ImClone, the developer of biologic drugs to... ...

Source: www.moreover.com --- 11 hours ago
Nature Oct 12 2008 4:19AM GMT ...

Source: www.moreover.com --- 1 day ago
Drug Discovery and Development Oct 11 2008 9:43AM GMT ...

Source: www.fiercepharma.com --- 1 day ago
Eli Lilly's $6.5 billion buyout of ImClone was greeted with great fanfare on Monday--by all but a few analysts who questioned whether Lilly's $70-a-share offer was a bit too rich for the times. Doubters suggested that the unprecedentedly tight credit markets might hinder Lilly's ability to raise $2 billion to $3 billion in financing. "These aren't ordinary circumstances," one analyst pointed out Tuesday in the New York Times . At the same time, Moody's and Standard & Poor's said they'd be looking at Lilly for a possible debt downgrade. And now, a top stock analyst has downgraded the company. Catherine Arnold of Credit Suisse now rates Lilly "neutral;" before the ImClone deal, the drugmaker rated an "outperform." Her concerns? Possible overpayment for ImClone, for one. For another, if Lilly forks over billions of cash--and assumes billions in debt--to wrap up the deal, it may have to forego future acquisitions. - read the item at the NYT 's DealBook blog Related Articles: Eli Lilly out to redesign itself as a biotech Pharma investing: A good bet? Crunch paves way for pharma deals U.S. pharma in a blue Moody over bad credit ...

Source: www.topix.com --- 1 day ago
Eli Lilly and Company and ImClone Systems Inc. recently announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all ... ...

Source: siegler.wordpress.com --- 16 hours ago
Eli Lilly & Co. has agreed to buy ImClone Systems Inc. in an agreement and plan of merger (link is to sample merger agreements, as the Eli Lilly - ImClone merger agreement hasn’t been made public yet) for more than $6 billion. The merger would broaden Eli Lilly’s pipeline of cancer treatments and represents a [...] ...

Source: www.topix.com --- 1 day ago
Shares of Eli Lilly and Co. plunged 12 percent Thursday to their lowest point since 1996, after an analyst said the Indianapolis drug maker's planned $6.5 billion purchase of a biotech company won't produce ... ...

Source: www.topix.com --- 1 day ago
Zacks Analyst Blog Highlights: Bristol-Myers Squibb Co., ImClone Systems Inc., LSI Corp, Infineon Technologies A.G. and ConocoPhillips. ...

Source: www.biotecnologica.com --- 1 day ago
La compañía farmacéutica Eli Lilly ha adquirido por un valor de 6.500 millones de dólares la firma biotecnológica ImClone Systems, la cual rechazó la oferta de su socio Bristol Myers que posee el 16.6% del capital de la compañía por un valor inferior al ofertado por Lilly. Con esta adquisión, Eli Lilly ampliará su negocio de [...] ...

Source: www.windybits.com --- 1 day ago
INDIANAPOLIS – Want to expand your product pipeline in hurry? Just buy a company that already has a hot item. Indianapolis-based pharma colossus Eli Lilly deployed this strategy earlier this week and broke a more than 100-year-old tradition when it snapped up ImClone for $6.5 billion in cash. ...

Source: www.farmanux.com --- 1 day ago
Eli Lilly's $6.5 billion buyout of ImClone was greeted with great fanfare on Monday--by all but a few analysts who questioned whether Lilly's $70-a-share offer was a bit too rich for the times. Doubters suggested that the unprecedentedly tight credit markets might hinder Lilly's ability to raise $2 billion to $3 billion in financing. "These aren't ordinary circumstances," one analyst pointed out Tuesday in the New York Times . At the same time, Moody's and Standard & Poor's said they'd be looking at Lilly for a possible debt downgrade. And now, a top stock analyst has downgraded the company. Catherine Arnold of Credit Suisse now rates Lilly "neutral;" before the ImClone deal, the drugmaker rated an "outperform." Her concerns? Possible overpayment for ImClone, for one. For another, if Lilly forks over billions of cash--and assumes billions in debt--to wrap up the deal, it may have to forego future acquisitions. - read the item at the NYT 's DealBook blog Related Articles: Eli Lilly out to redesign itself as a biotech Pharma investing: A good bet? Crunch paves way for pharma deals U.S. pharma in a blue Moody over bad credit ...

Source: www.chron.com --- 5 days ago
— WHAT HAPPENED: Indianapolis-based drug maker Eli Lilly & Co. is buying the biotech firm ImClone Systems Inc. for more than $6 billion. DEAL SPECIFICS: Lilly agreed to pay $70 per share in an all-cash offer it will finance with as much as $3 billion in debt. ...

Source: www.indystar.com --- 5 days ago
Bristol-Myers Squibb won't object to bid for cancer-drug maker; Lilly stock slips 7%, 11-year low. ...

Source: www.topix.com --- 1 day ago
John Lechleiter sounded gleeful Oct. 6 after writing a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. ...

Source: www.topix.com --- 1 day ago
Pharmaceutical giants face a conundrum, as illustrated by two recent events. Eli Lilly agreed to pay $6.5 billion in cash for ImClone Systems to get its hands on a roster of experimental cancer drugs. ...

Source: www.topix.com --- 1 day ago
BioSpace News Beat Weekly Recap A weekly round-up of biotech's top stories from around the world By Suvarna Bhatt, Feature Editor SAN FRANCISCO a ' ImClone Systems created a huge buzz when it announced on ... ...